A novel estrogen receptor GPER mediates proliferation induced by 17b-estradiol and selective GPER agonist G-1 in estrogen receptor α (ERα)-negative ovarian cancer cells

Cell Biology International

Volumn 38, Issue 5, 2014, Pages 631-638

  Liu, Huidi ^a   Yan, Yan ^a   Wen, Haixia ^a   Jiang, Xueli ^a   Cao, Xuefeng ^a   Zhang, Guangmei ^b   Liu, Guoyi ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Estrogen; GPER; Ovarian cancer; Proliferation

Indexed keywords

1 [4 (6 BROMOBENZO[1,3] DIOXOL 5 YL) 3A,4,5,9B TETRAHYDRO 3H CYCLOPENTA[C]QUINOLIN 8 YL]ETHANONE; AGENTS AFFECTING CELL DIVISION; CYCLIN D1; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; G PROTEIN COUPLED RECEPTOR 30; PERTUSSIS TOXIN; PROTEIN C FOS; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 1-(4-(6-BROMOBENZO(1,3)DIOXOL-5-YL)-3A,4,5,9B-TETRAHYDRO-3H-CYCLOPENTA(C)QUINOLIN-8-YL)ETHANONE; CYCLOPENTANE DERIVATIVE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA, HUMAN; G PROTEIN COUPLED RECEPTOR; GPER PROTEIN, HUMAN; QUINOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL ASSAY; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN OVCAR5; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIGAND BINDING; MARKER GENE; OVARY CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN RNA BINDING; PROTEIN TARGETING; UPREGULATION; WESTERN BLOTTING; AGONISTS; DRUG EFFECTS; FEMALE; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOPENTANES; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; OVARIAN NEOPLASMS; QUINOLINES; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84899108648     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1002/cbin.10243     Document Type: Article

References (32)

1. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Andò S, Maggiolini M (2007) G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 67(4): 1859-66.
2. Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, Cunliffe HE, Black MA, Donato AL, Arterburn JB, Oprea TI, Prossnitz ER, Dun NJ, Jordan VC (2010) The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res 70(3): 1184-94.
3. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck NP, Sklar LA, Oprea TI, Prossnitz ER (2006) Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2(4): 207-12.
4. Chan QK, Lam HM, Ng CF, Lee AY, Chan ES, Ng HK, Ho SM, Lau KM (2010) Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, cjun/ c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ 17(9): 1511-23.
5. Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PC (2001) Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology 142(6): 2351-60.
6. Curran T, Franza BR (1988) Fos and Jun: the AP-1 connection. Cell 55(3): 395-7.
7. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E (2006) Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 12(21): 6359-66.
8. Filardo EJ, Quinn JA, Frackelton AR, Bland KI (2002) Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol 16(1): 70-84.
9. Gao F, Ma X, Ostmann AB, Das SK (2011) GPR30 activation opposes estrogen-dependent uterine growth via inhibition of stromal ERK1/2 and estrogen receptor alpha (ERa) phosphorylation signals. Endocrinology 152(4): 1434-47.
10. Girgert R, Emons G, Gründker C (2012) Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy. Breast Cancer Res Treat 134(1): 199-205.
11. Hall JM, Couse JF, Korach KS (2001) The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 276(40): 36869-72.
12. He YY, Cai B, Yang YX, Liu XL, Wan XP (2009) Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway. Cancer Sci 100(6): 1051-61.
13. Ignatov T, Modl S, Thulig M, Weiβenborn C, Treeck O, Ortmann O, Zenclussen A, Costa SD, Kalinski T, Ignatov A (2013) GPER-1 acts as a tumor suppressor in ovarian cancer. J Ovarian Res 6(1): 51.
14. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2): 106-30.
15. Kim SM, Lee SY, Yuk DY, Moon DC, Choi SS, Kim Y, Han SB, Oh KW, Hong JT (2009) Inhibition of NF-kappaB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel. Arch Pharm Res 32(5): 755-65.
16. Kolkova Z, Casslén V, Henic E, Ahmadi S, Ehinger A, Jirström K, Casslén B (2012) The G protein-coupled estrogen receptor 1 (GPER/GPR30) does not predict survival in patients with ovarian cancer. J Ovarian Res 5: 9.
17. Lacey JV, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288(3): 334-41.
18. Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, Price RH, Pestell RG, Kushner PJ (2002) Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 277(27): 24353-60.
19. Lucas TF, Royer C, Siu ER, Lazari MF, Porto CS (2010) Expression and signaling of G protein-coupled estrogen receptor 1 (GPER) in rat sertoli cells. Biol Reprod 83(2): 307-17.
20. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, Montanaro D, Musti AM, Picard D, Andò S (2004) The G protein-coupled receptor GPR30 mediates c-fos upregulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem 279(26): 27008-16.
21. Prossnitz ER, Arterburn JB, Sklar LA (2007) GPR30: A G proteincoupled receptor for estrogen. Mol Cell Endocrinol 265-266: 138-42.
22. Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ (2008) Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol 70: 165-90.
23. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER (2005) A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307(5715): 1625-30.
24. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ (2001) Estrogen replacement therapy and ovarian cancermortality in a large prospective study of US women. JAMA 285(11): 1460-5.
25. Shaulian E, Karin M (2002) AP-1 as a regulator of cell life and death. Nat Cell Biol 4(5): E131-6.
26. Singh M, Sétáló G, Guan X, Frail DE, Toran-Allerand CD (2000) Estrogen-induced activation of the mitogen-activated protein kinase cascade in the cerebral cortex of estrogen receptor-alpha knock-out mice. J Neurosci 20(5): 1694-700.
27. Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE, Prossnitz ER (2009) GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol 114(3): 465-71.
28. Teng J, Wang ZY, Prossnitz ER, Bjorling DE (2008) The G protein-coupled receptor GPR30 inhibits human urothelial cell proliferation. Endocrinology 149(8): 4024-34.
29. Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A, Musti AM, Picard D, Andò S, MaggioliniM(2006a) 17betaestradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g proteincoupled receptor GPR30. Mol Pharmacol 70(4): 1414-23.
30. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Andò S, MaggioliniM (2006b) The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17betaestradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 20(3): 631-46.
31. Wang C, Lv X, He C, Hua G, Tsai MY, Davis JS (2013) The G-protein-coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian cancer cells by blocking tubulin polymerization. Cell Death Dis 4: e869.
32. Yan Y, Liu HD, Cao XF, Tan PZ, Lv CM, Li XM, Liu GY (2011) Expression of G protein-coupled receptor 30 (GPR30) in epithelial ovarian carcinoma and its correlation with proliferation associated genes c-fos and cyclinD1. Reprod Contracept 31: 236-40. [in Chinese].